LGI1-antibody Patients Follow-up

Anti-LGI1 Encephalitis Clinical Trial

— evoLGI1  

Official title:

Clinical, EEG and Radiological Initial and Evolutive Characterisation of LGI1-antibody Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04106765
• Other study ID #: evoLGI1
• Status: Not yet recruiting
• Start date: October 30, 2019
• Est. completion date: December 30, 2020

Study information

• Verified date: September 2019
• Source: Hospices Civils de Lyon
• Contact: Jerome HONNORAT, PhD
• Phone: 4 72 35 78 08
• Email: jerome.honnorat[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Autoimmune encephalitis involve autoantibodies targeting central nervous system, and particularly the synapse or its structure like for LGI1 protein. Anti-LGI1 encephalitis is revealed by an inflammation of the limbic system, with mainly temporal lobe, faciobrachial dystonic or generalized seizures, and cognitive disorders.

This disease is rare and its clinical, EEG and radiological characterisation is not sufficiently established. The investigators will evaluate these three aspects for the anti-LGI1 cohort of patients of the National Reference Center of autoimmune encephalitis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 192
• Est. completion date: December 30, 2020
• Est. primary completion date: September 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• Diagnosis of anti-LGI1 encephalitis based on sera or CSF samples in the National Reference Center of autoimmune encephalitis from 2011/06 to 2019 july 1st.

• Clinical follow-up in France

Exclusion Criteria:

• Anti-LGI1 antibody associated with another encephalitis antibody

• Foreign follow-up

Related Conditions & MeSH terms

• Anti-LGI1 Encephalitis
• Encephalitis

Locations

Country	Name	City	State
France	Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evolution of epileptic seizures		12 MONTHS